ArticleJournal of the American Academy of Dermatology2024

De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy.

Olivia S Jew et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.